Completed PHASE3 INTERVENTIONAL 6-arm NCT01707992

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Multiple Sclerosis

Interventions Laquinimod Placebo

Updated 12 times since 2017 Last updated: Nov 5, 2021 Started: Feb 20, 2013 Primary completion: Apr 13, 2015 Completion: Jul 4, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01707992, this PHASE3 trial focuses on Multiple Sclerosis and remains completed. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jun 2020 — Jan 2021 [monthly]

Completed PHASE3
May 2020 — Jun 2020 [monthly]

Completed PHASE3
Apr 2019 — May 2020 [monthly]

Completed PHASE3
Jun 2018 — Apr 2019 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Advance, United States , Athens, Greece , Aurora, United States , Bad Mergentheim, Germany , Baloteşti, Romania , Barcelona, Spain , Barnaul, Russia , Belgrade, Serbia , Bellevue, United States , Berg, Germany and 198 more locations